

ABSTRACT OF THE DISCLOSURE

This invention with a new compound enables application of L-Arginine made with arginine alpha-ketoglutarate, arginine pyroglutamate, arginine ketoisocaproate and ornithine alpha-ketoglutarate to work together and separately along with other ingredients, topically. It is intended to improve the process by which these compounds work in the human organism. The invention is based on the facts that L-Arginine is:

- known to be the immediate precursor of the endogenous vasodilator substance found in the arterial blood vessels called "Endothelium-Derived Relaxing Factor" (EDRF)
- required for protein synthesis and, depending on the organism's needs, can either be metabolized to support glucose synthesis or catabolized to produce energy

This simplified "noninvasive" application surpasses gastrointestinal digestion so the compounds will not degrade and favoring absorption into the circulatory system thus enhancing the compounds' effects and at much lower dosage levels than oral or parenteral administration.

A composition comprising L-Arginine to be used topically that creates increases in muscle size, strength, endurance and power output.